Intel Announces Board Member Departures Amid Focus On Industry Expertise
Intel Corp. has announced the retirement of three board members as it seeks to align expertise with its strategic direction.
Dr Omar Ishrak, Dr Tsu-Jae King Liu, and Dr Risa Lavizzo-Mourey will retire and not seek reelection at the company’s annual shareholder meeting on May 6, 2025.
The changes follow the appointment of Lip-Bu Tan as CEO, replacing Pat Gelsinger, as Intel continues its turnaround efforts in the semiconductor industry.
Dr Omar Ishrak joined Intel Corporation’s Board of Directors in 2017 and served as Chair from 2020 to 2023. He remains an Independent Director on the Board. He was Executive Chairman of Medtronic PLC until his retirement in 2020, having previously served as Chairman and CEO from 2011 to 2020. Before Medtronic, he spent 16 years at General Electric Co., where he was President and CEO of GE Healthcare Systems. Dr Ishrak is a board member of Amgen Inc. and Allurion Technologies Inc. He is also a trustee of the Asia Society and Minnesota Public Radio. He has served on the Board of Compute Health Acquisition Corp. Dr Ishrak holds a Bachelor of Science and a Ph.D. in electrical engineering from King’s College, University of London.
Dr Tsu-Jae King Liu joined Intel Corporation’s Board of Directors in 2016 as an Independent Director. She is the Dean and Roy W. Carlson Professor of Engineering at the University of California, Berkeley, where she is the first woman to hold the position. She also serves on the Board of MaxLinear Inc., a semiconductor products provider. Dr Liu holds over 90 patents and has received awards such as the Intel Outstanding Researcher in Nanotechnology Award (2012) and the SIA University Researcher Award (2014). Her research focuses on nanometre-scale logic and memory devices, as well as materials and process technology for energy-efficient electronics.
Dr Risa Lavizzo-Mourey joined Intel Corporation’s Board of Directors in 2018 as an Independent Director. She was the Robert Wood Johnson Foundation PIK Professor of Population Health and Health Equity at the University of Pennsylvania from 2018 to 2021. From 2003 to 2017, she served as president and CEO of the Robert Wood Johnson Foundation. She is a board member of GE Healthcare Technologies Inc. and Merck & Co. and has previously served on boards including General Electric Company, Better Therapeutics Inc., and Hess Corporation. Dr Lavizzo-Mourey is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. She holds an MBA from the University of Pennsylvania and a doctor of medicine from Harvard Medical School.
